Can we wean patients with inflammatory arthritis from biological therapies?
Can we wean patients with inflammatory arthritis from biological therapies?
复制标题
DOI：
10.1016/j.autrev.2019102399
复制
发表时间：
2019-12-01
影响因子：
13.6
通讯作者：
Kitas, George
中科院分区：
文献类型：
--
作者：
Edwards, Christopher J.;Galeazzi, Mauro;Kitas, George
生物疗法是治疗免疫介导的炎症性疾病的基石。它们的出现与目标治疗方法的实施相结合，意味着缓解或低疾病活动度现在已成为大量患者实现的现实治疗目标。然而，生物制品并非没有风险，其高昂的成本继续给国家医疗保健服务带来重要的经济负担。“我们可以让炎症性关节炎患者摆脱生物疗法吗？”在过去的十年中，这个问题变得越来越重要，因为要在功效、安全性和经济成果方面确定最佳的管理策略。毫不奇怪，这引发了一场有趣的争论，即逐渐减少生物制剂的理由是否超过不逐渐减少的理由，并且支持这两种学派的证据正在持续增长。 目的：在本文中，我们回顾了 2019 年佛罗伦萨风湿病学和自身免疫学争议会议相关会议的内容。
Biological therapies have represented a cornerstone in the treatment of immune-mediated inflammatory diseases. Their advent combined with implementation of a treat-to-target approach has meant that remission or low disease activity are now realistic targets for treatment achieved by a significant number of patients. However, biologicals are not risk free and their elevated costs continue to present an important economic burden to national healthcare services."Can we wean patients with inflammatory arthritis from biological therapies?"Over the last decade this question has become increasingly important as to define the best management strategies in terms of efficacy, safety and economic outcomes. Not surprisingly this has generated an interesting debate as to whether reasons to taper biologics outweigh reasons not to taper and evidence in support of either of these schools of thought is persistently growing.Aim: In this article we reviewed the contents of the relevant session from the 2019 Controversies in Rheumatology and Autoimmunity meeting in Florence.